Autopsy report · NCT03126864
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Cause of deathStaffing, sites or logistics
“Terminated per the PI's request.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 2 months before it stopped.
- 11 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Hematopoietic/Lymphoid Cancer; Acute Myeloid Leukemia
- Interventions
- Leukapheresis; Fludarabine; Cyclophosphamide; CD33-CAR-T Cell Infusion
- Participants
- 11
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
“Terminated per PI's request” - Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone
“terminated by PI” - Effectiveness of an Online Intervention Targeting Cancer-related Fatigue
“Terminated Per PI” - Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
“Closed at PI's Request” - Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression
“Terminated due to PI resignation. Not related to safety, efficacy, or administrative mandate.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.